← All trials
NCT05347771
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- Apr 26, 2022
- Last posted
- Jun 6, 2022
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- RegeneronCollaborator
- Rho, Inc.Collaborator
- University of WisconsinStudy chair
- University of WisconsinOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.